Replimune Group, Inc. stock drops after a second FDA rejection for RP1 melanoma; cash runway <12 months. Click for more on ...
Trials of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, are documenting its direct kidney effects and broad benefits for diabetic kidney disease.
In a bar, a poet meets the man behind the drug that saved his life — discovering how science, faith and chance created a future thought impossible.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results